Drug Companies Accelerate Development of Ketamine-Based Medicines

This development comes after the Trump administration showed support for psychedelic medicine, encouraging researchers to explore both new and existing forms of ketamine as treatments. Drug companies are responding by speeding up efforts to bring ketamine-based medicines to market.

Originally published by nyt